Arginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications
Standard
Arginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications. / Grosse, Gerrit M; Schwedhelm, Edzard; Worthmann, Hans; Choe, Chi-Un.
in: INT J MOL SCI, Jahrgang 21, Nr. 5, 05.03.2020.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Arginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications
AU - Grosse, Gerrit M
AU - Schwedhelm, Edzard
AU - Worthmann, Hans
AU - Choe, Chi-Un
PY - 2020/3/5
Y1 - 2020/3/5
N2 - The amino acid L-arginine serves as substrate for the nitric oxide synthase which is crucial in vascular function and disease. Derivatives of arginine, such as asymmetric (ADMA) and symmetric dimethylarginine (SDMA), are regarded as markers of endothelial dysfunction and have been implicated in vascular disorders. While there is a variety of studies consolidating ADMA as biomarker of cerebrovascular risk, morbidity and mortality, SDMA is currently emerging as an interesting metabolite with distinct characteristics in ischemic stroke. In contrast to dimethylarginines, homoarginine is inversely associated with adverse events and mortality in cerebrovascular diseases and might constitute a modifiable protective risk factor. This review aims to provide an overview of the current evidence for the pathophysiological role of arginine derivatives in cerebrovascular ischemic diseases. We discuss the complex mechanisms of arginine metabolism in health and disease and its potential clinical implications in diverse aspects of ischemic stroke.
AB - The amino acid L-arginine serves as substrate for the nitric oxide synthase which is crucial in vascular function and disease. Derivatives of arginine, such as asymmetric (ADMA) and symmetric dimethylarginine (SDMA), are regarded as markers of endothelial dysfunction and have been implicated in vascular disorders. While there is a variety of studies consolidating ADMA as biomarker of cerebrovascular risk, morbidity and mortality, SDMA is currently emerging as an interesting metabolite with distinct characteristics in ischemic stroke. In contrast to dimethylarginines, homoarginine is inversely associated with adverse events and mortality in cerebrovascular diseases and might constitute a modifiable protective risk factor. This review aims to provide an overview of the current evidence for the pathophysiological role of arginine derivatives in cerebrovascular ischemic diseases. We discuss the complex mechanisms of arginine metabolism in health and disease and its potential clinical implications in diverse aspects of ischemic stroke.
U2 - 10.3390/ijms21051798
DO - 10.3390/ijms21051798
M3 - SCORING: Review article
C2 - 32150996
VL - 21
JO - INT J MOL SCI
JF - INT J MOL SCI
SN - 1661-6596
IS - 5
ER -